Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block …

[Read the full article here]

Comments are closed.